Denosumab therapies are used to increase bone mass and treat osteoporosis, as well as address bone complications in cancer.

Biocon announced that Health Canada has granted a Notice of Compliance (NOC) for Bosaya (denosumab), a biosimilar to Prolia, and Vezuo (denosumab), a biosimilar to Xgeva, on 03 April 2026. Both ...

On February 13, 2025, the FDA approved Samsung Bioepis Co., Ltd.’s denosumab biosimilars, OSPOMYV™ (denosumab-dssb; 60 mg pre-filled syringe) and XBRYK™ (denosumab-dssb; 120 mg vial), referencing ...

Dr. Reddy’s and Alvotech shared that the Food and Drug Administration has accepted a 351(k) Biologic License Application submission for AVT03, which was developed by Alvotech, and is a proposed ...

Health Canada has granted Biocon a Notice of Compliance for its denosumab biosimilars Bosaya and Vevzuo, referencing Prolia ...

Biocon receives Health Canada's compliance notice for biosimilars Bosaya and Vevzuo, enhancing treatment options for ...